Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company that discovers and develops breakthrough treatments for immune-mediated and oncological disorders, today announced the appointment of Gitanjali Jain as vice-president President of Investor Relations and External Affairs. As a member of the management team and executive committee, Ms. Jain will lead all of Kezar’s investor relations, public relations and science communications efforts.
“We are delighted to welcome Gita to the team as we continue to work to provide new therapies for patients living with difficult conditions,” said John Fowler, co-founder and CEO of Kezar Life Sciences. “Gita’s strong relationship with investors and proven track record of success in the industry will add tremendous value to Kezar, and I look forward to working in partnership with her.
“I am delighted to join Kezar at a pivotal time for the company as we continue to advance KZR-616, our first immunoproteasome inhibitor and KZR-261, our first protein secretion inhibitor,” said Ms. Jain. “I am honored to be able to contribute to the team and to Kezar’s future growth as we work to create therapies that address areas where patient needs are not being met. ”
Gita joins Kezar with over 15 years of experience in the healthcare industry. Prior to Kezar, she was Managing Director of Solebury Trout, where she advised over 50 biopharmaceutical companies on business strategy, investor relations, communications and capital market transactions. Previously, she worked in the laboratory as a research associate at Medarex and StemCells, Inc. Gita holds a master’s degree in biology from New York University, a bachelor’s degree in economics from Brown University and has previously been designated Financial Industry Regulator (FINRA) Series 7, 63 and 79 Principal Licensee in Finance and Operations.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company that discovers and develops breakthrough treatments for immune-mediated and oncological disorders. The company is a pioneer in the field of first-class small molecule therapies that harness key regulators of cellular function to inhibit multiple disease factors via unique and potent targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261 is the company’s first clinical anticancer candidate targeting the Sec61 translocon and the protein secretion pathway. An IND application for KZR-261 in solid tumors was filed in August 2021, and Kezar plans to initiate a phase 1 open label dose escalation clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors. For more information, visit www.kezarlifesciences.com.
Caution regarding forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “should”, “expect”, “believe” and phrases Similar words (as well as other words or phrases referring to future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar’s clinical development programs, results or future performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, without limitation, statements about the design, advancement, timing, scope and results of clinical trials, the expected timing of the disclosure of clinical trial results and the planned regulatory development of Kezar product candidates. Orphan drug designation does not provide any guarantee of regulatory approval or expedited regulatory review. Many factors can cause current expectations to differ from actual results, including the impacts of the COVID-19 pandemic on the business, clinical trials and financial condition of the company, unexpected safety data or d efficacy observed during preclinical or clinical studies, activation or recruitment of clinical trial sites. lower than expected fares, changes in expected or existing competition, changes in the regulatory environment, uncertainties and timing of the regulatory approval process, and unforeseen litigation or other disputes. Other factors that could cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the documents filed by Kezar with the United States Securities and Exchange Commission, including the “risk factors” contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.